Home Neurologic and Psychiatric Genetic Markers LRRK2 Genetic Test: Parkinson Disease Risk and Results

LRRK2 Genetic Test: Parkinson Disease Risk and Results

By
Vita Library
-
3
Understand LRRK2 genetic testing for Parkinson disease, including pathogenic variants, penetrance, family risk, uncertain results, and clinical next steps.

An LRRK2 genetic test looks for variants in one gene that can substantially increase the chance of Parkinson disease. The most widely recognized variant is p.G2019S, but several other pathogenic LRRK2 variants are known. A positive result does not mean that an unaffected person will definitely develop Parkinson disease, because LRRK2 has reduced and age-dependent penetrance. It also cannot predict an exact age of onset, symptoms, or rate of progression. In a person who already has Parkinson disease, a pathogenic result may explain part of the cause, clarify risk for relatives, and support eligibility for LRRK2-focused research. Testing can be performed as a single-gene study, targeted analysis for a family variant, or part of a broader Parkinson disease panel. Interpretation requires the exact variant, ancestry, family history, clinical status, and laboratory classification. Genetic counseling is especially important before testing an unaffected relative because the result can affect family communication, reproductive choices, and decisions about privacy and insurance.

  • Pathogenic LRRK2 variants raise Parkinson disease risk but do not guarantee disease.
  • Risk increases with age and differs by variant, ancestry, family, and study method.
  • p.G2019S is common in some Ashkenazi Jewish and North African populations but occurs worldwide.
  • A variant of uncertain significance should not be used to predict Parkinson disease.
  • Each child of a carrier has a 50% chance of inheriting the variant, not a 50% certainty of developing disease.
  • Current routine treatment is based on symptoms, although genetic results may open research options.

Table of Contents

What LRRK2 does

LRRK2 stands for leucine-rich repeat kinase 2. The gene provides instructions for a large protein involved in several cellular processes, including signaling, membrane trafficking, lysosome function, and immune activity. Certain pathogenic variants increase LRRK2 kinase activity or otherwise disturb its function. These changes can contribute to degeneration of dopamine-producing neurons and the development of Parkinson disease.

LRRK2-related Parkinson disease often resembles more typical, apparently sporadic Parkinson disease. Common motor features include slowness, stiffness, resting tremor, and balance problems. People can also develop constipation, depression, anxiety, cognitive change, sleep disturbance, reduced smell, blood-pressure symptoms, and other nonmotor features. No symptom pattern proves that LRRK2 is involved, and some carriers have fewer of particular nonmotor features than other people with Parkinson disease. Clinical overlap is substantial.

LRRK2 is usually described as a monogenic Parkinson disease gene because a single pathogenic variant can create a major inherited susceptibility. However, it is not fully penetrant. Some carriers live into older age without developing Parkinson disease. This is different from a deterministic variant that is expected to cause disease in nearly every carrier. It is also different from a common low-effect risk marker that changes risk only slightly.

Age is the strongest established factor affecting penetrance. Risk rises as carriers grow older, but published estimates vary widely because studies recruit different families, ancestries, age groups, and populations. Recent large datasets have estimated p.G2019S penetrance lower than some earlier family-based studies. A laboratory report should therefore not present one lifetime percentage as universally correct.

Other genes and environmental exposures may modify whether or when disease develops. Researchers have identified polygenic and biological modifiers, but these are not yet precise enough to tell one carrier what will happen. Lifestyle factors associated with Parkinson disease risk in populations also do not provide a proven way to prevent LRRK2-related disease.

The test detects inherited susceptibility; it does not measure dopamine neurons, diagnose current motor symptoms, or show whether disease has begun. A movement-disorder examination remains the basis for determining whether someone has Parkinson disease. Imaging or biomarker studies may support evaluation in selected settings, but they do not replace clinical assessment or change the meaning of the DNA variant.

Who may consider testing

A person with Parkinson disease may consider LRRK2 testing to investigate cause, inform relatives, and determine possible research eligibility. Testing has traditionally been emphasized for people with several affected relatives, younger onset, or ancestry in which particular variants are more frequent. As access expands and gene-targeted studies develop, some programs now offer broader testing to adults with Parkinson disease even without these features.

Family history remains useful. A pattern of Parkinson disease across successive generations can suggest dominant inheritance. Yet the pattern may be incomplete because LRRK2 penetrance is reduced, relatives may die before onset, diagnoses may be inaccurate, or family size may be small. A person can carry a pathogenic variant despite reporting no affected relatives.

An unaffected adult with a known familial LRRK2 variant can choose predictive testing. The most informative approach is targeted testing for the exact variant already confirmed in an affected relative. Testing should be voluntary. A relative’s wish to know, a research team’s interest, or family pressure should not substitute for the individual’s informed decision.

Predictive testing can be useful for people who want to resolve uncertainty, make reproductive plans, or consider observational research. It can also create anxiety without providing a definite forecast or proven preventive treatment. Pretest counseling explores what each possible result would change, who will provide support, and whether there are current mental health or life circumstances that make postponing the decision reasonable.

Testing children for an adult-onset, incompletely penetrant LRRK2 variant is generally not recommended when there is no childhood medical action. The future adult should usually decide whether to learn this information. Testing a minor’s sample for family research is a separate ethical question and does not automatically justify returning a predictive clinical result.

People with atypical parkinsonism should not assume LRRK2 is the best or only test. Early severe autonomic failure, prominent eye-movement abnormalities, rapidly progressive dementia, marked cerebellar signs, or early falls can point toward another diagnosis. Conversely, typical Parkinson disease can result from many genetic and non-genetic factors. A broader Parkinson disease genetic test may be more appropriate when no family variant is known.

Direct-to-consumer testing may include p.G2019S or a small set of ancestry-associated variants. A negative consumer result does not sequence the full gene, and a positive result should be confirmed in a clinical laboratory before medical or family decisions are made.

Which variants the test finds

The best-known pathogenic LRRK2 variant is p.G2019S, also written c.6055G>A. It is a founder variant in Ashkenazi Jewish and North African Berber populations and is also found in people from many other backgrounds. Its frequency among people with Parkinson disease differs greatly by ancestry and geographic region.

Other established pathogenic variants affect important LRRK2 protein domains. Examples include p.R1441C, p.R1441G, p.R1441H, p.Y1699C, and p.I2020T. Some are enriched in particular families or populations, such as p.R1441G in the Basque region. Their penetrance and clinical data are not identical to p.G2019S, so counseling should be variant-specific whenever evidence permits.

Several variants, including p.G2385R and p.R1628P, are more common risk factors in some Asian populations. These generally confer a smaller increase in risk than classic pathogenic variants and should not be described as fully equivalent. A laboratory may classify and report them differently depending on test purpose and policy. The report should clearly distinguish a pathogenic dominant variant from a susceptibility allele.

A targeted familial-variant test checks only the known change. It is the preferred method for relatives when the family result is established. Full LRRK2 sequencing evaluates coding exons and nearby splice boundaries for many small variants. Deletion/duplication analysis may be added, although large copy-number changes are not a common cause of LRRK2-related Parkinson disease. A panel evaluates LRRK2 alongside genes such as GBA1, SNCA, PRKN, PINK1, PARK7, VPS35, and others.

The laboratory must classify each variant using clinical, population, segregation, and functional evidence. Pathogenic and likely pathogenic variants can support LRRK2-related risk. Benign and likely benign variants do not. A variant of uncertain significance, or VUS, lacks enough evidence and should not be used to tell an unaffected person that they are at increased risk.

Not every rare LRRK2 missense change is harmful. LRRK2 is a large gene with many naturally occurring variants. Computer predictions or a statement that a change affects a “conserved” amino acid are not enough by themselves. A robust classification uses multiple independent evidence types and should be updated if important new data emerge.

Clinical confirmation should use the exact transcript and protein notation. The report should specify whether the result was found in one or both gene copies, although carrying two p.G2019S copies does not appear to produce a simple doubling of penetrance. Samples from relatives can help determine whether a novel candidate variant tracks with disease, but segregation alone may be difficult to interpret because some carriers remain unaffected.

How to interpret a positive result

In a person with clinically diagnosed Parkinson disease, a pathogenic LRRK2 variant provides a likely genetic contributor. It does not prove that every symptom is caused by the variant, and it does not exclude additional genetic or acquired factors. Treatment decisions continue to depend on the person’s manifestations, response to medication, cognition, balance, and other health conditions.

In an unaffected person, the result means increased age-related risk, not a current diagnosis. Penetrance estimates for p.G2019S have ranged substantially. A recent large online-cohort analysis cited in GeneReviews estimated about 24% penetrance by age 80, while earlier studies reported higher values in selected families and populations. Differences do not mean one study is necessarily “wrong”; they show that ascertainment, ancestry, age structure, modifiers, and diagnostic methods matter.

Some rarer pathogenic variants may have higher reported penetrance, but estimates are often based on smaller families and can be imprecise. A counselor should discuss the quality and relevance of evidence for the exact variant rather than borrowing the p.G2019S number. Even a high estimate cannot determine an individual outcome.

A positive result cannot forecast age of onset. LRRK2-related Parkinson disease can begin across a wide adult age range. It also cannot reliably predict whether tremor, gait difficulty, cognitive change, or another feature will dominate. Group averages may describe a somewhat slower motor course or different nonmotor profile for some p.G2019S cohorts, but individual variation is broad.

The result should not be interpreted using simple arithmetic. A 50% chance of inheriting the variant is not multiplied mechanically by one penetrance percentage to produce a fixed personal risk for every child. Risk changes with age and depends on the variant and context. Genetic counseling can explain conditional risk without false precision.

Finding a pathogenic LRRK2 variant may have emotional effects even in someone already diagnosed. It can bring an explanation but also concern about children and siblings. Some people feel guilt about transmission, although no one chose or caused the inherited change. A family-centered discussion can separate responsibility from biology.

A positive result can also identify trial opportunities. LRRK2 kinase inhibitors and other pathway-focused therapies are under study, but no genetic result guarantees eligibility or benefit. Trial status changes, and early biological effects do not automatically translate into slower clinical progression. Current claims should be checked with the trial registry and treating specialist.

What negative and uncertain results mean

A negative targeted familial test means the person did not inherit the specific LRRK2 variant found in the family, assuming the family result and biological relationships are correct. That person does not have the variant-related increase in risk and cannot pass that variant to children. Their general population risk of Parkinson disease and risk from other factors remain.

A negative full-gene test has a different meaning. It shows that the laboratory did not identify a reportable LRRK2 variant with the methods used. It does not rule out Parkinson disease, because most people with Parkinson disease do not have an identifiable pathogenic LRRK2 variant. It also does not exclude variants in other genes or complex genetic susceptibility.

The report’s scope matters. A test limited to p.G2019S will miss other pathogenic variants. A genotyping array covers only predefined sites. Full sequencing may still miss deep intronic, regulatory, structural, or mosaic changes. When family history strongly suggests dominant Parkinson disease, a comprehensive panel or updated analysis may be considered.

A VUS is an unresolved laboratory finding. It should not prompt predictive testing of healthy relatives, change reproductive decisions, or be used as the explanation for Parkinson disease without stronger evidence. Testing affected and unaffected relatives may contribute information in selected families, but because penetrance is incomplete, a single unaffected carrier does not settle classification.

A common risk allele is not a diagnostic positive. Some reports may include variants associated with modest changes in odds. These findings are influenced by ancestry and population data and usually have far less predictive value than a pathogenic p.G2019S-like variant. The report should state the effect type rather than using the broad word “mutation.”

Reclassification can occur. A VUS may later become benign, likely benign, likely pathogenic, or pathogenic as functional studies and population datasets improve. The ordering clinic should know whether the laboratory issues amended reports. People should keep a copy of the original result and update contact information, but they should not repeatedly retest the same pathogenic variant.

When symptoms are present but the genetic result is negative or uncertain, clinical care should proceed based on the neurologic diagnosis. Genetic testing is an added layer of information, not a gatekeeper for treatment.

Inheritance and family testing

Pathogenic LRRK2 variants are inherited in an autosomal dominant pattern. A carrier has one altered copy and one usual copy of the gene. Each biological child has a 50% chance of inheriting the variant. This probability resets in every pregnancy. Children who inherit it face increased age-related risk, but some never develop Parkinson disease.

Siblings of a carrier may also be at risk. If one parent is known to carry the variant, each sibling has a 50% chance of inheriting it. When neither parent has been tested, the family cannot assume which side carries the variant. A pathogenic variant may occasionally be de novo, but an apparently negative family history is more often explained by reduced penetrance, limited family size, late onset, or incomplete information.

The most useful first family test is usually the affected relative. Confirming a pathogenic LRRK2 variant in someone with Parkinson disease establishes the family finding. Predictive testing in unaffected adults can then target that exact variant. Broad testing of an unaffected relative before the affected person may produce a VUS without clarifying the family pattern.

Predictive testing should include informed consent and attention to privacy. Laws protecting genetic information differ by country and may treat health, employment, life, disability, and long-term-care insurance differently. People should obtain current local advice before testing rather than relying on general online statements.

Reproductive options include natural conception, prenatal diagnosis, and in vitro fertilization with preimplantation genetic testing. Because penetrance is reduced and onset is usually in adulthood, families may weigh these options differently. The purpose of counseling is to explain risks and methods, not to direct a particular decision. Testing an embryo or pregnancy requires a confirmed familial variant and advance laboratory coordination.

A result can reveal information about relatives who did not ask to know. The tested person controls their own medical information, but sharing the exact variant may allow relatives to make informed choices. A genetics clinic can provide a neutral family letter. Communication should say that relatives may be at risk, not that they have Parkinson disease.

An autosomal dominant inheritance result can be deceptively simple on paper. Reduced penetrance, age dependence, and uncertain estimates make LRRK2 counseling more nuanced than the 50% transmission figure alone.

Clinical care and research

For someone with Parkinson disease, the LRRK2 result does not replace standard treatment. Levodopa and other dopaminergic therapies are chosen according to symptoms, age, side effects, and personal goals. Physical activity, physical therapy, speech and swallowing care, occupational therapy, sleep management, mood treatment, and fall prevention remain central. Deep brain stimulation may be considered using the same clinical criteria applied to other appropriate patients.

The genotype may influence monitoring in research but does not create a separate universally accepted clinical surveillance schedule. Clinicians assess movement, cognition, mood, sleep, autonomic symptoms, medication effects, and safety. New symptoms should be evaluated rather than assumed to be genetic or inevitable.

For an unaffected carrier, there is no proven medication that prevents LRRK2-related Parkinson disease. Routine repeated dopamine imaging, spinal fluid testing, or blood biomarkers are not established population screening. Some observational studies offer structured assessments, smell testing, digital measures, imaging, or biomarker collection to understand early change. Participation is optional and may not provide individual clinical benefit.

Regular exercise is associated with broad health benefits and may support mobility, mood, sleep, and cardiovascular health. It should be encouraged as general health care, not promised as a way to neutralize a pathogenic variant. Avoidance of smoking is advisable for overall health even though some epidemiologic associations with Parkinson disease can be misunderstood. No supplement, pesticide “detox,” special diet, or consumer program has been shown to prevent LRRK2-related disease.

LRRK2 is an active therapeutic target because several pathogenic variants increase kinase activity and the pathway may matter beyond genetic carriers. Clinical trials have tested small-molecule inhibitors and other approaches. Results must be interpreted cautiously: reaching the biological target, changing a biomarker, and slowing disability are separate questions. A 2026 update on one broad LRRK2 inhibitor program reported acceptable target effects but no clear slowing in the overall Parkinson disease cohort, with continued study planned in genetically defined participants.

Research eligibility may depend on the exact variant, diagnosis, disease stage, age, medications, kidney or lung health, and trial location. A clinical laboratory result is often required. People should discuss risks, placebo design, travel, costs, and post-trial access with the study team and their own neurologist.

Planning the next step

Before ordering testing, identify the question. Is the goal to explain Parkinson disease, test for a known family variant, estimate future risk in an unaffected adult, plan a pregnancy, or seek a trial? The right assay and counseling process differ for each purpose.

If Parkinson disease is already diagnosed and no family variant is known, a multigene panel is often more informative than LRRK2 alone. It should include high-confidence Parkinson disease genes and clinically important risk genes, with methods appropriate for copy-number variants and difficult regions. The person should know whether the panel reports GBA1, secondary findings, or low-effect risk alleles.

If a relative has a positive report, obtain the actual laboratory document rather than relying on a remembered gene name. “LRRK2 positive” can refer to a pathogenic variant, a VUS, or a common risk allele. Targeted family testing should use the exact cDNA and protein notation and a laboratory that can confirm the classification.

After a positive result, arrange a genetics visit to review penetrance, family risk, and reproductive implications. A person with symptoms should continue movement-disorder care. An unaffected carrier can choose whether to establish a baseline examination or join research; there is no requirement to live as though disease is imminent.

After a negative result, ask whether the assay matched the question. A negative p.G2019S test may justify broader sequencing if the clinical or family history remains suggestive. A negative comprehensive panel does not invalidate the Parkinson diagnosis. Reanalysis may become useful as gene evidence and test technology improve.

After a VUS, avoid predictive testing or irreversible decisions based on the finding. Ask what evidence would resolve it and whether the laboratory has a reclassification process. A VUS result explanation can help distinguish uncertainty from elevated risk.

Seek prompt clinical assessment for new tremor, slowness, stiffness, persistent balance change, dream enactment with injury, marked loss of smell with other neurologic signs, or functional decline. These features are not specific to LRRK2 and can have other causes. The most responsible use of testing is to combine a technically reliable result with realistic risk language, individualized neurologic care, and respect for each family member’s choice about knowing.

References

Disclaimer

This article is general educational information and does not replace individual assessment by a neurologist, genetics professional, or genetic counselor. LRRK2 penetrance estimates vary, and only a qualified team with the exact laboratory report can interpret a result for one person or family. Do not change medication, surveillance, insurance, or reproductive plans based on consumer data or an uncertain variant alone.

RELATED ARTICLESMORE FROM AUTHOR